Sustainable Protocol for the Synthesis of 2′,3′-Dideoxynucleoside and 2′,3′-Didehydro-2′,3′-dideoxynucleoside Derivatives
作者:Virginia Martín-Nieves、Yogesh S. Sanghvi、Susana Fernández、Miguel Ferrero
DOI:10.3390/molecules27133993
日期:——
ribonucleosides into 2’,3’-dideoxynucleoside and 2’,3’-didehydro-2’,3’-dideoxynucleoside derivatives, including the anti-HIV drugs stavudine (d4T), zalcitabine (ddC) and didanosine (ddI), was established. The process involves radical deoxygenation of xanthate using environmentally friendly and low-cost reagents. Bromoethane or 3-bromopropanenitrile was the alkylating agent of choice to prepare the
将核糖核苷转化为 2',3'-二脱氧核苷和 2',3'-二脱氢-2',3'-二脱氧核苷衍生物的改进方案,包括抗 HIV 药物司他夫定 (d4T)、扎西他滨 (ddC) 和去羟肌苷 (ddI) 成立。该过程涉及使用环保和低成本的试剂对黄原酸盐进行自由基脱氧。溴乙烷或 3-溴丙腈是制备核糖核苷 2',3'-双黄原酸酯的首选烷化剂。在随后的自由基脱氧反应中,三(三甲基甲硅烷基)硅烷和 1,1'-偶氮二(环己烷甲腈)分别被用来代替有害的 Bu 3 SnH 和 AIBN。此外,在 5'- O的脱保护步骤中,TBAF 取代了樟脑磺酸。-甲硅烷基醚基团和一种酶(腺苷脱氨酶)用于将 2',3'-二脱氧腺苷转化为 2',3'-二脱氧肌苷 (ddI),产率很高。